{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-26-000011","form_type":"8-K/A","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2026-07-13T20:06:29+00:00","discovered_at":"2026-07-13T20:08:00.402932+00:00","generated_at":"2026-07-13T20:08:11.696207+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioMarin provides Amicus audited 2025 financials; revenue $634M, net loss $27M","bullets":["Amicus 2025 net product sales $634.2M, up 20% YoY from $528.3M; net loss narrowed to $27.1M from $56.1M.","Amicus had $214.0M cash, $392.7M long-term debt, and $2.77B accumulated deficit as of Dec 31, 2025.","BioMarin acquired Amicus for $14.50/share in cash, closing April 27, 2026; this filing provides audited financials and pro forma.","Amicus revenue concentrated: one customer accounted for 24% of 2025 net product sales.","Pro forma condensed combined financials as of Dec 31, 2025 included in Exhibit 99.2."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-26-000011","json":"https://secwatch.observer/filing/0001048477-26-000011.json","markdown":"https://secwatch.observer/filing/0001048477-26-000011.md","text":"https://secwatch.observer/filing/0001048477-26-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847726000011/0001048477-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847726000011/bmrn-20260427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T20:08:11.696207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}